SCHEMBL14129152

SCHEMBL14129152

CCCCN(CCCC)c1ccc(/C=C(\C#N)C(=O)OCCOCCOCCC)cc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.48
DNM1 Q05193 3/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
POLB P06746 2/20 0.48
SLC16A3 O15427 2/20 0.47
SLC16A1 P53985 2/20 0.47
KDM4E B2RXH2 1/20 0.46
MAPK1 P28482 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
APP P05067 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12633782 0.94 APP (0.51) MAPTDNM1ALDH1A1MEN1KMT2A
SCHEMBL14129171 0.90 MEN1 (0.60) MAPTDNM1ALDH1A1MEN1KMT2A
SCHEMBL15371855 0.87 ALDH1A1 (0.53) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL14129149 0.86 MEN1 (0.57) MAPTDNM1ALDH1A1MEN1KMT2A
SCHEMBL15491698 0.86 MAPT (0.46) MAPTDNM1ALDH1A1MEN1KMT2A
SCHEMBL17732471 0.86 APP (0.45) MAPTDNM1ALDH1A1MEN1KMT2A
SCHEMBL17732481 0.85 SLC16A3 (0.45) MAPTDNM1ALDH1A1MEN1KMT2A
SCHEMBL15491090 0.84 SLC16A3 (0.46) MAPTDNM1ALDH1A1MEN1KMT2A
SCHEMBL1781017 0.84 SLC16A3 (0.55) MAPTALDH1A1MEN1KMT2APOLB
SCHEMBL1781014 0.84 SLC16A3 (0.55) MAPTALDH1A1MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180126008-A1 Methods Of Preparing Ophthalmic Formulations And Uses Of Same COGNOPTIX, INC. 2018-05-10 US disclosed
US-20170315137-A1 AMYLOID BINDING AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-11-02 US disclosed
US-9551722-B2 Amyloid binding agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-01-24 US disclosed
US-20160278677-A1 Method for Measuring Fluorescence in Ocular Tissue COGNOPTIX, INC. 2016-09-29 US disclosed
US-20150177262-A1 AMYLOID BINDING AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-06-25 US disclosed
US-20150118163-A1 Methods of Preparing Ophthalmic Formulations and Uses of Same COGNOPTIX, INC. 2015-04-30 US disclosed
US-20120302603-A1 AMYLOID BINDING AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302603-A1 AMYLOID BINDING AGENTS APP, APBA1, PSEN1 MAPT 6/4885DNM1 1564/4885ALDH1A1 3897/4885
US-20170315137-A1 AMYLOID BINDING AGENTS APBA1, APP, PSEN1 MAPT 5/4885DNM1 1359/4885ALDH1A1 4267/4885
US-20160278677-A1 Method for Measuring Fluorescence in Ocular Tissue ALDH1A2, FUCA1, EYA3 MAPT 2162/4885DNM1 277/4885ALDH1A1 673/4885
US-20180126008-A1 Methods Of Preparing Ophthalmic Formulations And Uses Of Same PDE6G, PDE6A, F12 MAPT 318/4885DNM1 1335/4885ALDH1A1 1932/4885
US-20150118163-A1 Methods of Preparing Ophthalmic Formulations and Uses of Same PDE6G, PDE6A, F12 MAPT 318/4885DNM1 1335/4885ALDH1A1 1932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.